Larimar Therapeutics Inc stock is traded at $2.38, with a volume of 166,434. It is up +2.37% in the last 24 hours and down -14.57% over the past month. Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Previous Close:
$2.32
Open:
$2.36
24h Volume:
166,434
Relative Volume:
0.13
Market Cap:
$246.72M
Revenue:
-
Net Income/Loss:
-$166.01M
P/E Ratio:
-
EPS:
-$2.08
Net Cash Flow:
-$131.32M
1W Performance:
-3.85%
1M Performance:
-14.57%
6M Performance:
-42.77%
1Y Performance:
-31.56%
1-Day Range:
$2.30$2.47
1-Week Range:
$2.26$2.83
52-Week Range:
$1.92$6.42
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Name
Larimar Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
844-511-9056Address
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS